4//SEC Filing
Kassberg Thomas Richard 4
Accession 0000950170-24-026661
CIK 0001515673other
Filed
Mar 4, 7:00 PM ET
Accepted
Mar 5, 8:19 PM ET
Size
12.1 KB
Accession
0000950170-24-026661
Insider Transaction Report
Form 4
Kassberg Thomas Richard
CBO & Senior Vice President
Transactions
- Award
Common Stock
2024-03-01+17,800→ 264,660 total - Award
Common Stock
2024-03-01+957→ 265,617 total - Tax Payment
Common Stock
2024-03-01$53.69/sh−274$14,711→ 265,343 total - Sale
Common Stock
2024-03-01$53.76/sh−1,011$54,351→ 264,332 total - Award
Stock Option (Right to Buy)
2024-03-01+31,400→ 31,400 totalExercise: $53.69Exp: 2034-03-01→ Common Stock (31,400 underlying)
Footnotes (6)
- [F1]Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
- [F2]Represents shares of common stock which previously granted performance stock units were converted on March 1, 2024 upon certification of the performance metric.
- [F3]Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs.
- [F4]Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
- [F5]Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
- [F6]On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.
Documents
Issuer
Ultragenyx Pharmaceutical Inc.
CIK 0001515673
Entity typeother
Related Parties
1- filerCIK 0001303811
Filing Metadata
- Form type
- 4
- Filed
- Mar 4, 7:00 PM ET
- Accepted
- Mar 5, 8:19 PM ET
- Size
- 12.1 KB